Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)

Neurology 2026

View at publisher
Authors: Amit Bar-Or, Jiwon Oh, Gavin Giovannoni, Maria Pia Sormani, Martin S. Weber, Sharon Stoll, Jacqueline A. Nicholas, H.-Christian von Büdingen, Jon Lopez, Louise Roberts, Miriam Triyatni, Qi Qi
+5 more John N. Ratchford, Julie A. Napieralski, Alexandra Goodyear, Stephen L. Hauser, Ludwig Kappos
DOI: 10.1212/wnl.0000000000216067
Cited by: 1

Abstract

To evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary progressive multiple sclerosis (pwPPMS).

Fields of Study & Subjects

Multiple Sclerosis Research Studies Peripheral Neuropathies and Disorders Multiple Myeloma Research and Treatments

Publication details

Journal / source
Neurology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Volume
106
Issue
11_Supplement_1
Publication date
9 June 2026
Language
EN